Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 28, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Chinese Coronavirus, Johnson and Johnson, Wuhan Coronavirus, coronavirus
The coronavirus continues to spread across the globe as the US launch their first trials for Gilead’s ebola drug remdesivir in treating COVID-19. This comes at a time where US domestic supplies of 150 drugs are under threat from the epidemic.
In other news, MIT researchers have identified a new antibiotic compound using a machine-learning algorithm while Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection.
10. FDA advisory committee narrowly backs Eli Lilly’s Cyramza combo for metastatic EGFR+ NSCLC
Eli Lilly’s Cyramza (ramucirumab) has edged closer to US approval after it scored a recommendation from the FDA’s Oncologic Drugs Advisory Committee (ODAC).
9. New Johnson & Johnson study aiming to add stroke detection to Apple Watch
Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection.
8. NICE rejects Roche’s Polivy combo in relapsed or refractory diffuse large B-cell lymphoma
It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab and bendamustine, in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adult patients who are not eligible for haematopoietic stem cell transplant.
7.US Judge rules that a decade of unpublished trial results must be made public
A federal judge in New York’s Southern District has ruled that 10 years of unpublished clinical trial data must now be made public – a judgement which could have vast implications for possibly over 1,000 unpublished studies between 2007 and 2017.
6. Scotland’s life sciences sector on track to break $8 billion by 2025
A new report from the Scottish Government has revealed that the country’s life sciences sector is on track to breeze past its turnover target of $8 billion by the year 2025, thanks to strong and consistent growth over the past seven years.
5. New antibiotic discovered by AI for the first time
MIT researchers have identified a new antibiotic compound using a machine-learning algorithm.
4. US domestic supply of 150 drugs under threat from coronavirus outbreak
Disruption to the US drug production pipeline from the coronavirus could hurt its domestic supply of 150 drugs.
3. Clover Biopharmaceuticals partners up with GSK to accelerate coronavirus vaccine development
Chinese biotech firm Clover Biopharmaceuticals has joined the race to develop interventions against the ongoing coronavirus outbreak with the announcement that it has partnered up with GlaxoSmithKline (GSK) to aid in development of its protein-based “COVID-19 S-Trimer” vaccine.
2. First US coronavirus trial launched into Gilead’s remdesivir
The first US clinical trial investigating a treatment for the COVID-19 coronavirus has been launched by the US National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).
1. FDA approves first adjuvanted quadrivalent flu vaccine in over-65s
The FDA has just authorised its first adjuvanted quadrivalent influenza vaccine, it has been announced. Seqirus’ Fluad Quadrivalent (influenza vaccine, adjuvanted) has been approved in the US to for the prevention of seasonal vaccine in patients over the age of 65.
Related Content
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application …
Pharmafile.com’s weekly COVID-19 news round-up
The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with …
GSK’s Phase II otilimab study on COVID-19 patients promising for over-70s
GlaxoSmithKline’s (GSK) Phase II OSCAR study of their otilimab antibody’s effect on COVID-19 patients has …
